136 related articles for article (PubMed ID: 15635286)
1. [Characterization and cytotoxicity of mixed PEG-DSG modified liposomes].
Sadzuka Y; Tsuruda T; Sonobe T
Yakugaku Zasshi; 2005 Jan; 125(1):149-57. PubMed ID: 15635286
[TBL] [Abstract][Full Text] [Related]
2. Effects of mixed polyethyleneglycol modification on fixed aqueous layer thickness and antitumor activity of doxorubicin containing liposome.
Sadzuka Y; Nakade A; Hirama R; Miyagishima A; Nozawa Y; Hirota S; Sonobe T
Int J Pharm; 2002 May; 238(1-2):171-80. PubMed ID: 11996821
[TBL] [Abstract][Full Text] [Related]
3. Characterization and cytotoxicity of mixed polyethyleneglycol modified liposomes containing doxorubicin.
Sadzuka Y; Sugiyama I; Tsuruda T; Sonobe T
Int J Pharm; 2006 Apr; 312(1-2):83-9. PubMed ID: 16457972
[TBL] [Abstract][Full Text] [Related]
4. Study on the characterization of mixed polyethyleneglycol modified liposomes containing doxorubicin.
Sadzuka Y; Nakade A; Tsuruda T; Sonobe T
J Control Release; 2003 Sep; 91(3):271-80. PubMed ID: 12932707
[TBL] [Abstract][Full Text] [Related]
5. Characterization of novel mixed polyethyleneglycol modified liposomes.
Sugiyama I; Sadzuka Y
Biol Pharm Bull; 2007 Jan; 30(1):208-11. PubMed ID: 17202690
[TBL] [Abstract][Full Text] [Related]
6. Enhanced antitumor activity of different double arms polyethyleneglycol-modified liposomal doxorubicin.
Sugiyama I; Sadzuka Y
Int J Pharm; 2013 Jan; 441(1-2):279-84. PubMed ID: 23194885
[TBL] [Abstract][Full Text] [Related]
7. Correlation of fixed aqueous layer thickness around PEG-modified liposomes with in vivo efficacy of antitumor agent-containing liposomes.
Sugiyama I; Sadzuka Y
Curr Drug Discov Technol; 2011 Dec; 8(4):357-66. PubMed ID: 22034853
[TBL] [Abstract][Full Text] [Related]
8. Does the amount of an antitumor agent entrapped in liposomes influence its tissue distribution and cell uptake?
Sadzuka Y; Hirota S
Cancer Lett; 1998 Sep; 131(2):163-70. PubMed ID: 9851249
[TBL] [Abstract][Full Text] [Related]
9. Change in the character of liposomes as a drug carrier by modifying various polyethyleneglycol-lipids.
Sugiyama I; Sadzuka Y
Biol Pharm Bull; 2013; 36(6):900-6. PubMed ID: 23727913
[TBL] [Abstract][Full Text] [Related]
10. Effect of polyethyleneglycol (PEG) chain on cell uptake of PEG-modified liposomes.
Sadzuka Y; Kishi K; Hirota S; Sonobe T
J Liposome Res; 2003 May; 13(2):157-72. PubMed ID: 12855110
[TBL] [Abstract][Full Text] [Related]
11. Octreotide-modification enhances the delivery and targeting of doxorubicin-loaded liposomes to somatostatin receptors expressing tumor in vitro and in vivo.
Sun M; Wang Y; Shen J; Xiao Y; Su Z; Ping Q
Nanotechnology; 2010 Nov; 21(47):475101. PubMed ID: 21030757
[TBL] [Abstract][Full Text] [Related]
12. Effects of administered route on tissue distribution and antitumor activity of polyethyleneglycol-coated liposomes containing adriamycin.
Sadzuka Y; Nakai S; Miyagishima A; Nozawa Y; Hirota S
Cancer Lett; 1997 Jan; 111(1-2):77-86. PubMed ID: 9022131
[TBL] [Abstract][Full Text] [Related]
13. Effects of Surface Charge, PEGylation and Functionalization with Dipalmitoylphosphatidyldiglycerol on Liposome-Cell Interactions and Local Drug Delivery to Solid Tumors via Thermosensitive Liposomes.
Petrini M; Lokerse WJM; Mach A; Hossann M; Merkel OM; Lindner LH
Int J Nanomedicine; 2021; 16():4045-4061. PubMed ID: 34163158
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of antitumor effect of doxorubicin by its complexation with gamma-cyclodextrin in pegylated liposomes.
Arima H; Hagiwara Y; Hirayama F; Uekama K
J Drug Target; 2006 May; 14(4):225-32. PubMed ID: 16777681
[TBL] [Abstract][Full Text] [Related]
15. Enhanced circulation time and antitumor activity of doxorubicin by comblike polymer-incorporated liposomes.
Han HD; Lee A; Hwang T; Song CK; Seong H; Hyun J; Shin BC
J Control Release; 2007 Jul; 120(3):161-8. PubMed ID: 17524514
[TBL] [Abstract][Full Text] [Related]
16. Sustained liver targeting and improved antiproliferative effect of doxorubicin liposomes modified with galactosylated lipid and PEG-lipid.
Wang S; Xu H; Xu J; Zhang Y; Liu Y; Deng YH; Chen D
AAPS PharmSciTech; 2010 Jun; 11(2):870-7. PubMed ID: 20490957
[TBL] [Abstract][Full Text] [Related]
17. [To Assess Drug Delivery System Nanocarrier at Industrial Production: Establishment of Liposomal Surface Using Physicochemical Properties].
Sadzuka Y
Yakugaku Zasshi; 2024; 144(1):61-69. PubMed ID: 38171797
[TBL] [Abstract][Full Text] [Related]
18. Effect of hybridized liposome by novel modification with some polyethyleneglycol-lipids.
Sugiyama I; Sonobe T; Sadzuka Y
Int J Pharm; 2009 May; 372(1-2):177-83. PubMed ID: 19429278
[TBL] [Abstract][Full Text] [Related]
19. In vivo study of doxorubicin-loaded cell-penetrating peptide-modified pH-sensitive liposomes: biocompatibility, bio-distribution, and pharmacodynamics in BALB/c nude mice bearing human breast tumors.
Ding Y; Cui W; Sun D; Wang GL; Hei Y; Meng S; Chen JH; Xie Y; Wang ZQ
Drug Des Devel Ther; 2017; 11():3105-3117. PubMed ID: 29123382
[TBL] [Abstract][Full Text] [Related]
20. An efficient PEGylated liposomal nanocarrier containing cell-penetrating peptide and pH-sensitive hydrazone bond for enhancing tumor-targeted drug delivery.
Ding Y; Sun D; Wang GL; Yang HG; Xu HF; Chen JH; Xie Y; Wang ZQ
Int J Nanomedicine; 2015; 10():6199-214. PubMed ID: 26491292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]